Inoviq Ltd has released a press release.
Disease Specificity study completed for NeuCA15-3 test
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Inoviq
- EXO-OC test delivers outstanding performance
- AGM CEO Presentation
- INOVIQ receives $1m RDTI refund
- Quarterly Business Update and Appendix 4C - September 2024
- NEURO-NET validated in Parkinson's
Later from Inoviq
- Weaponising Exosomes for Breast Cancer treatment
- Quarterly Business Update and Appendix 4C - December 2024
- Appendix 4D and FY25 Half Year Financial Report
- Quarterly Business Update and Appendix 4C - March 2025
- Pause in Trade
Follow Inoviq into a list and get an email when it puts out news.
Follow Inoviq